LSV Asset Management Has $853,000 Stake in Alkermes plc $ALKS

LSV Asset Management grew its holdings in shares of Alkermes plc (NASDAQ:ALKS) by 106.1% in the 4th quarter, Holdings Channel reports. The fund owned 30,500 shares of the company’s stock after buying an additional 15,700 shares during the period. LSV Asset Management’s holdings in Alkermes were worth $853,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. UBS Group AG grew its holdings in shares of Alkermes by 237.4% during the fourth quarter. UBS Group AG now owns 2,544,895 shares of the company’s stock worth $71,206,000 after purchasing an additional 1,790,729 shares during the last quarter. Baker BROS. Advisors LP grew its holdings in shares of Alkermes by 26.2% during the third quarter. Baker BROS. Advisors LP now owns 8,091,351 shares of the company’s stock worth $242,741,000 after purchasing an additional 1,680,748 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of Alkermes by 1,070.6% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,208,944 shares of the company’s stock worth $36,268,000 after purchasing an additional 1,105,666 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Alkermes by 787.2% during the second quarter. BNP Paribas Financial Markets now owns 1,135,478 shares of the company’s stock worth $32,486,000 after purchasing an additional 1,007,488 shares during the last quarter. Finally, American Century Companies Inc. grew its holdings in shares of Alkermes by 20.2% during the third quarter. American Century Companies Inc. now owns 4,397,471 shares of the company’s stock worth $131,924,000 after purchasing an additional 740,248 shares during the last quarter. Institutional investors and hedge funds own 95.21% of the company’s stock.

Alkermes Price Performance

Shares of NASDAQ:ALKS opened at $38.09 on Thursday. The company has a quick ratio of 1.70, a current ratio of 2.27 and a debt-to-equity ratio of 0.85. Alkermes plc has a twelve month low of $25.17 and a twelve month high of $39.56. The stock’s 50 day moving average is $33.95 and its 200-day moving average is $31.68. The firm has a market capitalization of $6.35 billion, a price-to-earnings ratio of 42.32 and a beta of 0.31.

Alkermes (NASDAQ:ALKS) last issued its earnings results on Saturday, February 14th. The company reported $0.29 earnings per share for the quarter. Alkermes had a return on equity of 9.26% and a net margin of 9.78%.The company had revenue of $384.55 million for the quarter. Sell-side analysts forecast that Alkermes plc will post -0.43 EPS for the current fiscal year.

Insider Transactions at Alkermes

In other news, EVP Craig C. Hopkinson sold 9,000 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $33.40, for a total transaction of $300,600.00. Following the transaction, the executive vice president directly owned 81,389 shares of the company’s stock, valued at $2,718,392.60. This represents a 9.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christian Todd Nichols sold 6,000 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $30.00, for a total value of $180,000.00. Following the transaction, the senior vice president directly owned 109,769 shares in the company, valued at $3,293,070. The trade was a 5.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 39,102 shares of company stock valued at $1,265,090 over the last ninety days. 4.59% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ALKS. Bank of America boosted their price target on Alkermes from $34.00 to $36.00 and gave the stock a “neutral” rating in a report on Thursday, April 9th. Truist Financial upgraded Alkermes to a “strong-buy” rating in a report on Wednesday, March 25th. HC Wainwright restated a “neutral” rating and set a $43.00 price target on shares of Alkermes in a report on Thursday, February 26th. Wall Street Zen cut Alkermes from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Finally, UBS Group boosted their price target on Alkermes from $42.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $45.40.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.